# A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection

> **NCT02604212** · PHASE2 · TERMINATED · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** ARC-520
- **OTHER:** Placebo
- **DRUG:** entecavir
- **DRUG:** antihistamine
- **DRUG:** tenofovir

## Key facts

- **NCT ID:** NCT02604212
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Company decision to discontinue trial
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02604212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02604212, "A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02604212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*